top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)

AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.

Click here now for the full details of this stock that’s set to rocket in the AI revolution…

Spiro Kevin Sakiris net worth and biography

Spiro Sakiris Biography and Net Worth

Insider of GBS

Presently, Spiro Kevin Sakiris is Chief Financial Officer of GBS, Inc. (New York). Mr. Sakiris is also on the board of Econ Financial Services Pty Ltd. and Ecapital Investments (No.1) Pty Ltd. and Member of The Institute of Chartered Accountants in Australia, Member of Institute of Chartered Accountants of New Zealand and Principal at Iq Capital Usa LLC.

In the past Mr. Sakiris held the position of Group Chief Operating & Financial Officer at The iQ Group Global Ltd., Secretary for IQX Ltd., COO, Chief Financial Officer & Executive Director at IQ3Corp Ltd., Chief Operating Officer for FarmaForce Ltd. and Partner at Economos Chartered Accountants.

Spiro Kevin Sakiris received an undergraduate degree from the University of Technology Sydney.

What is Spiro Kevin Sakiris' net worth?: The estimated net worth of Spiro Kevin Sakiris is at least $133,606.48 as of June 22nd, 2022. Mr. Sakiris owns 50,228 shares of GBS stock worth more than $133,606 as of April 23rd. This net worth approximation does not reflect any other investments that Mr. Sakiris may own. Additionally, Mr. Sakiris receives a salary of $292,450.00 as Insider at GBS. Learn More about Spiro Kevin Sakiris' net worth.
How old is Spiro Kevin Sakiris?: Mr. Sakiris is currently 60 years old. There are 3 older executives and no younger executives at GBS. The oldest executive at GBS is Dr. Stephen Constantine Boyages M.D., MBBS, Ph.D., Interim CEO & Chairman, who is 64 years old. Learn More on Spiro Kevin Sakiris' age.
What is Spiro Kevin Sakiris' salary?: As the Insider of GBS Inc., Mr. Sakiris earns $292,450.00 per year. The highest earning executive at GBS is Mr. Harry Simeonidis, Pres of Asia Pacific, who commands a salary of $354,710.00 per year. Learn More on Spiro Kevin Sakiris' salary.
How do I contact Spiro Kevin Sakiris?: The corporate mailing address for Mr. Sakiris and other GBS executives is , , . GBS can also be reached via phone at 646 828 8258 and via email at [email protected]. Learn More on Spiro Kevin Sakiris' contact information.
Has Spiro Kevin Sakiris been buying or selling shares of GBS?: Spiro Kevin Sakiris has not been actively trading shares of GBS within the last three months. Most recently, on Wednesday, June 22nd, Spiro Kevin Sakiris bought 5,000 shares of GBS stock. The stock was acquired at an average cost of $0.65 per share, with a total value of $3,250.00. Following the completion of the transaction, the chief financial officer now directly owns 50,228 shares of the company's stock, valued at $32,648.20. Learn More on Spiro Kevin Sakiris' trading history.
Who are GBS's active insiders?: GBS's insider roster includes Tom Parmakellis (Director), and Spiro Sakiris (Insider). Learn More on GBS's active insiders.

Spiro Kevin Sakiris Insider Trading History at GBS

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
6/22/2022	Buy	5,000	$0.65	$3,250.00	50,228
6/17/2022	Buy	15,970	$0.61	$9,741.70	45,228
12/6/2021	Buy	10,000	$1.70	$17,000.00

Spiro Kevin Sakiris Buying and Selling Activity at GBS

GBS Company Overview

GBS Inc. operates as a biosensor diagnostic technology company in the Asia-Pacific and North America. It offers Saliva Glucose Biosensor, an organic thin-film transistor for diabetes management that measures glucose in saliva. The company also focuses on developing SARS-CoV-2 Biosensor, a biosensor test can be used as a complement to the (RNA) virus detection test; and a biosensor platform comprising of biochemistry, immunology, tumor markers, hormones, and nucleic acid diagnostic modalities. GBS Inc. has a research agreement with Johns Hopkins Bloomberg School of Public Health for the development of saliva-based diagnostic tests. The company was formerly known as Glucose Biosensor Systems (Greater China) Holdings, Inc. and changed its name to GBS Inc. in September 2019. The company was incorporated in 2016 and is headquartered in New York, New York. GBS Inc. is a subsidiary of Life Science Biosensor Diagnostics Pty Ltd.

Today's Range

Now: $2.66

$2.57

$2.78

50 Day Range

MA: $4.21

$2.74

$6.00

2 Week Range

Now: $2.66

$0.36

$2.89

Volume

60,974 shs

Average Volume

955,325 shs

Market Capitalization

$39.61 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.32

top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)

From Traders Agency | Ad